Enric Carcereny, Teresa Morán, Laia Capdevila, Sara Cros, Laia Vilà, Maria de Los Llanos Gil, Jordi Remón, Rafael Rosell
{"title":"The epidermal growth factor receptor (EGRF) in lung cancer.","authors":"Enric Carcereny, Teresa Morán, Laia Capdevila, Sara Cros, Laia Vilà, Maria de Los Llanos Gil, Jordi Remón, Rafael Rosell","doi":"10.1186/s40247-015-0013-z","DOIUrl":null,"url":null,"abstract":"<p><p>In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer. </p>","PeriodicalId":90074,"journal":{"name":"Translational respiratory medicine","volume":"3 ","pages":"1"},"PeriodicalIF":0.0000,"publicationDate":"2015-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s40247-015-0013-z","citationCount":"34","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40247-015-0013-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 34
Abstract
In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor (EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer. Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an overview of the EGFR pathway and options for its treatment of lung cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
